Intratumoral treatment with PeptiBAC with poly-lysine-containing modified gp70 antigen increases the number of responders to anti-PD-1 therapy, improves tumor control and induces tumor-specific T cell responses in a syngeneic mouse model of CT26 colorectal cancer. Here, EMB is linked to neoplasm.